Latest News & Features
Americas
A US court has ruled that biotechnology company Regeneron engaged in “inequitable conduct” after finding that it withheld information from a patent application for a genetically modified mouse. 11 August 2015
Americas
Medical device makers Ethicon Endo-Surgery, a subsidiary of Johnson & Johnson, and Covidien will head back to a US court after the US Court of Appeals for the Federal Circuit revived their patent dispute concerning ultrasonic surgical devices. 10 August 2015
Americas
Law firm Gibson Dunn has hired Jane Love and Robert Trenchard as partners in its New York office. 10 August 2015
Europe
Proactively managing patent portfolios is an investment that pays for itself in reduced patent costs. Bruno Reynolds, who works at the consultancy arm of Isis Innovation, the technology transfer company of the University of Oxford, explains more. 6 August 2015
Americas
The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio. 6 August 2015
Americas
Drugs companies Sandoz and Lupin have failed to reverse a US court’s ruling that they infringed patents owned by Allergan. 5 August 2015
Africa
Worldwide applications for pharmaceutical patents “peaked sharply” in 2014, reaching around 28,000, a report has shown. 4 August 2015
Americas
A Brazilian court has confirmed that a eucalyptus breed produced by biotechnology company Eldorado Brasil Celulose is genetically identical to pulp producer Fibria Celulose’s own cultivar product VTO2. 4 August 2015
Americas
Pharmaceutical company Celgene has requested that the US Patent and Trademark Office sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”. 31 July 2015
Americas
TWi Pharmaceuticals has released a generic version of the Megace ES drug, which is used to treat certain symptoms experienced by AIDS patients, just one day after a court ruled that it did not infringe a patent owned by Par Pharmaceutical. 30 July 2015